TNFAIP3 and acute lymphoblastic leukemia: Moreover, RMST was used to evaluate the performance of the Kaplan–Meier curve, and the 3‐year RMST for T‐ALL patients with and without TNFAIP3 mutation was 14 (95% CI: 6–22) and 26 (95% CI: 22–30) months, respectively (Figure 3A).